← Back to Screener
KALA BIO, Inc. Common Stock (KALA)
Price$0.19
Favorite Metrics
Price vs S&P 500 (26W)-91.32%
Price vs S&P 500 (4W)-27.09%
Market Capitalization$181.17M
All Metrics
Book Value / Share (Quarterly)$0.88
P/TBV (Annual)0.88x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.25
Price vs S&P 500 (YTD)-66.88%
Gross Margin (TTM)30.96%
Net Profit Margin (TTM)-1383.48%
EPS (TTM)$-5.94
10-Day Avg Trading Volume2.94M
EPS Excl Extra (TTM)$-5.94
EPS (Annual)$-10.26
ROI (Annual)-91.19%
Gross Margin (Annual)34.19%
Net Profit Margin (5Y Avg)-7795.15%
Cash / Share (Quarterly)$6.54
ROA (Last FY)-70.29%
EBITD / Share (TTM)$-5.30
ROE (5Y Avg)-413.54%
Operating Margin (TTM)-1261.57%
Cash Flow / Share (Annual)$-4.86
P/B Ratio31.74x
P/B Ratio (Quarterly)6.48x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)29.49x
Net Interest Coverage (TTM)-12.60x
ROA (TTM)-64.88%
EPS Incl Extra (Annual)$-10.26
Current Ratio (Annual)3.11x
Quick Ratio (Quarterly)1.96x
3-Month Avg Trading Volume7.67M
52-Week Price Return-94.30%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.17
P/S Ratio (Annual)46.57x
Asset Turnover (Annual)0.04x
52-Week High$20.60
Operating Margin (5Y Avg)-7404.03%
EPS Excl Extra (Annual)$-10.26
CapEx CAGR (5Y)-31.10%
Tangible BV CAGR (5Y)-26.70%
26-Week Price Return-87.34%
Quick Ratio (Annual)3.02x
13-Week Price Return-68.94%
Total Debt / Equity (Annual)2.47x
Current Ratio (Quarterly)1.99x
Enterprise Value$169.574
Asset Turnover (TTM)0.05x
Book Value / Share Growth (5Y)-45.58%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.60x
Pretax Margin (Annual)-1152.19%
Cash / Share (Annual)$8.40
3-Month Return Std Dev121.51%
Net Income / Employee (TTM)$-1
ROE (Last FY)-316.25%
Net Interest Coverage (Annual)-11.32x
EPS Basic Excl Extra (Annual)$-10.26
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)5.37x
EPS Incl Extra (TTM)$-5.94
Receivables Turnover (Annual)0.00x
ROI (TTM)-83.84%
P/S Ratio (TTM)31.51x
Pretax Margin (5Y Avg)-7795.15%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$11.12
Price vs S&P 500 (52W)-124.13%
Year-to-Date Return-64.24%
5-Day Price Return8.63%
EPS Normalized (Annual)$-10.26
ROA (5Y Avg)-69.35%
Net Profit Margin (Annual)-1152.19%
Month-to-Date Return14.85%
Cash Flow / Share (TTM)$-21.40
EBITD / Share (Annual)$-10.20
Operating Margin (Annual)-958.61%
LT Debt / Equity (Annual)1.63x
ROI (5Y Avg)-94.88%
LT Debt / Equity (Quarterly)2.65x
EPS Basic Excl Extra (TTM)$-5.94
P/TBV (Quarterly)1.49x
P/B Ratio (Annual)3.43x
Inventory Turnover (TTM)0.60x
Pretax Margin (TTM)-1383.48%
Book Value / Share (Annual)$2.02
Price vs S&P 500 (13W)-69.63%
Beta-2.10x
Revenue / Share (TTM)$0.00
ROE (TTM)-366.61%
52-Week Low$0.15
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.29
2.29
2.29
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KALAKALA BIO, Inc. Common Stock | 31.51x | — | 30.96% | — | $0.19 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Kala Bio is a clinical-stage biopharmaceutical company developing cell-derived therapies for rare eye diseases. The company's lead candidate, KPI-012, is a human mesenchymal stem cell product designed to restore corneal healing and treat severe retinal degenerative diseases including Retinitis Pigmentosa and Stargardt Disease. KPI-012 leverages multiple therapeutic factors including growth factors and neuroprotective proteins to address unmet needs in vision-threatening conditions.